Download PDF
J Neurol Surg B Skull Base 2021; 82(03): 285-294
DOI: 10.1055/s-0039-1696724
Original Article

Factors Associated with and Temporal Trends in the Use of Radiation Therapy for the Treatment of Pituitary Adenoma in the National Cancer Database

Ramie Fathy
1   University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
,
Edward Kuan 
2   Department of Otolaryngology, University of California Irvine, Irvine, California, United States
,
John Y. K. Lee
3   Department of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
,
M Sean Grady
3   Department of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
,
Michelle Alonso-Basanta
4   Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
,
James N. Palmer
5   Department of Otorhinolaryngology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
,
Nithin D. Adappa
6   Department of Otorhinolaryngology Head and Neck Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
,
Bert W. O'Malley Jr.
6   Department of Otorhinolaryngology Head and Neck Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
,
Jason Brant
6   Department of Otorhinolaryngology Head and Neck Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Objective Radiation therapy represents an uncommon but important component of treatment plans for some pituitary adenomas (PAs). Although radiation therapy has been used to treat pituitary adenomas for over a century, general trends in the usage of radiation therapy for this purpose have not been reviewed. Additionally, there are few large studies evaluating how radiation therapy is used for the treatment of these benign tumors. Investigating these trends and identifying any variations in radiation therapy utilization would help to better inform treatment decisions and improve patient outcomes.

Design Present study is a retrospective analysis of cases using the National Cancer Database.

Setting The research was organized at a tertiary academic medical center.

Participants Patients were diagnosed with pituitary adenoma between 2004 and 2014 within the National Cancer Database (NCDB).

Methods Temporal trends in the usage of radiation therapy to treat pituitary adenoma were analyzed through a retrospective analysis of 77,142 pituitary adenoma cases from the NCDB between 2004 and 2014. Univariate and multivariate analyses were to examine the relationship between patient, tumor, and treatment factors, and the incorporation of radiation therapy into the treatment of pituitary adenomas. We adjusted for potential confounders such as age, sex, race, comorbidity score, facility type, and year of diagnosis.

Results A total of 77,142 patients met inclusion criteria. Inclusion of radiation therapy in pituitary adenoma treatment was 8.0% in 2004 and steadily declined to a low of 3.1% in 2014. Overall, patients were less likely to receive radiation for their pituitary adenoma over time (p < 0.001). Similarly, patients were found to be less likely to receive any type of treatment for PA over time (p < 0.001). Multivariable evaluation found patients who were female, between 54 and 64 years of age, or treated at either a Comprehensive Community Cancer Program or an Integrated Network Cancer Program were more likely to receive radiation as part of their pituitary adenoma treatment (p < 0.001, odds ratio [OR] = 2.01, confidence interval [CI]: 1.54–2.63; p < 0.001, OR = 1.84, CI: 1.38–2.44, respectively). Patients were less likely to receive radiation for their PA if they were African American (p < 0.001, OR = 0.81, CI: 0.72–0.91). Logistic regression also identified a progressive increase in the likelihood of receiving radiation after a PA diagnosis with increasing tumor size starting with microscopic tumors, peaking at 4 to 5 cm (p < 0.001; OR = 15.57; CI: 12.20–19.87).

Conclusion In this sample of pituitary adenoma patients treated at NCDB institutions between 2004 and 2014, we found a steady decline in the incorporation of radiation therapy in treatment, as well as in the use of any type of intervention for PA treatment, suggesting a rise in noninterventional observation of PA.

Keywords

radiation therapy - pituitary adenoma - national cancer database - temporal trends - radiation - watchful waiting - skull base - anterior skull base


Publication History

Received: 29 March 2019

Accepted: 28 July 2019

Article published online:
04 October 2019

© 2019. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Laws Jr. ER, Ebersold MJ, Piepgras DG, Randall RV, Salassa RM. The results of transsphenoidal surgery in specific clinical entities. In: Management of Pituitary Adenomas and Related Lesions with Emphasis on Transsphenoidal Microsurgery. New York, NY: Appleton-Century-Crofts Inc.; 1982: 277-305
    Google Scholar
  • 2 Laws Jr. ER, Vance ML. Radiosurgery for pituitary tumors and craniopharyngiomas. Neurosurg Clin N Am 1999; 10 (02) 327-336
    CrossrefPubMedGoogle Scholar
  • 3 Sheehan JP, Xu Z, Lobo MJ. External beam radiation therapy and stereotactic radiosurgery for pituitary adenomas. Neurosurg Clin N Am 2012; 23 (04) 571-586
    CrossrefPubMedGoogle Scholar
  • 4 Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011; 96 (07) 1992-2003
    CrossrefPubMedGoogle Scholar
  • 5 Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab 2000; 85 (04) 1420-1425
    PubMedGoogle Scholar
  • 6 Shibui S. [The present status and trend of brain tumors based on the data of the Brain Tumor Registry of Japan]. Brain Nerve 2012; 64 (03) 286-290
    PubMedGoogle Scholar
  • 7 Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-oncol 2012; 14 (Suppl. 05) v1-v49
    CrossrefPubMedGoogle Scholar
  • 8 Aflorei ED, Korbonits M. Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol 2014; 117 (03) 379-394
    CrossrefPubMedGoogle Scholar
  • 9 Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro-oncol 2001; 3 (03) 152-158
    PubMedGoogle Scholar
  • 10 Ezzat S, Asa SL, Couldwell WT. et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004; 101 (03) 613-619
    CrossrefPubMedGoogle Scholar
  • 11 Fernández-Balsells MM, Murad MH, Barwise A. et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metab 2011; 96 (04) 905-912
    CrossrefPubMedGoogle Scholar
  • 12 Nammour GM, Ybarra J, Naheedy MH, Romeo JH, Aron DC. Incidental pituitary macroadenoma: a population-based study. Am J Med Sci 1997; 314 (05) 287-291
    PubMedGoogle Scholar
  • 13 Yue NC, Longstreth Jr. WT, Elster AD, Jungreis CA, O'Leary DH, Poirier VC. Clinically serious abnormalities found incidentally at MR imaging of the brain: data from the Cardiovascular Health Study. Radiology 1997; 202 (01) 41-46
    CrossrefPubMedGoogle Scholar
  • 14 Hartwigsen G, Siebner HR, Deuschl G, Jansen O, Ulmer S. Incidental findings are frequent in young healthy individuals undergoing magnetic resonance imaging in brain research imaging studies: a prospective single-center study. J Comput Assist Tomogr 2010; 34 (04) 596-600
    CrossrefPubMedGoogle Scholar
  • 15 Vernooij MW, Ikram MA, Tanghe HL. et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007; 357 (18) 1821-1828
    CrossrefPubMedGoogle Scholar
  • 16 Ryu WH, Tam S, Rotenberg B. et al. Conservative management of pituitary macroadenoma contacting the optic apparatus. Can J Neurol Sci 2010; 37 (06) 837-842
    CrossrefPubMedGoogle Scholar
  • 17 Iglesias P, Arcano K, Triviño V. et al. Prevalence, clinical features, and natural history of incidental clinically non-functioning pituitary adenomas. Horm Metab Res 2017; 49 (09) 654-659
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Powell JS, Wardlaw SL, Post KD, Freda PU. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 2000; 85 (05) 2068-2071
    PubMedGoogle Scholar
  • 19 Mitsumori M, Shrieve DC, Alexander III E. et al. Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 1998; 42 (03) 573-580
    CrossrefPubMedGoogle Scholar
  • 20 Landolt AM, Haller D, Lomax N. et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 1998; 88 (06) 1002-1008
    CrossrefPubMedGoogle Scholar
  • 21 Brada M, Rajan B, Traish D. et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993; 38 (06) 571-578
    CrossrefPubMedGoogle Scholar
  • 22 Erridge SC, Conkey DS, Stockton D. et al. Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiother Oncol 2009; 93 (03) 597-601
    CrossrefPubMedGoogle Scholar
  • 23 Tishler RB, Loeffler JS, Lunsford LD. et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 1993; 27 (02) 215-221
    CrossrefPubMedGoogle Scholar
  • 24 Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J. Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys 2010; 76 (3, Suppl): S28-S35
    CrossrefPubMedGoogle Scholar
  • 25 Pollock BE, Cochran J, Natt N. et al. Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys 2008; 70 (05) 1325-1329
    CrossrefPubMedGoogle Scholar
  • 26 Sheehan JP, Starke RM, Mathieu D. et al. Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J Neurosurg 2013; 119 (02) 446-456
    CrossrefPubMedGoogle Scholar
  • 27 Park HS, Decker RH. Disparities in radiation therapy delivery: current evidence and future directions in head and neck cancer. Cancers Head Neck 2016; 1 (01) 5
    CrossrefPubMedGoogle Scholar
  • 28 Vinod SK, Simonella L, Goldsbury D, Delaney GP, Armstrong B, O'Connell DL. Underutilization of radiotherapy for lung cancer in New South Wales, Australia. Cancer 2010; 116 (03) 686-694
    CrossrefPubMedGoogle Scholar
  • 29 Goulart BHL, Reyes CM, Fedorenko CR. et al. Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer. J Oncol Pract 2013; 9 (01) 42-50
    CrossrefPubMedGoogle Scholar
  • 30 Freeman HP, Chu KC. Determinants of cancer disparities: barriers to cancer screening, diagnosis, and treatment. Surg Oncol Clin N Am 2005; 14 (04) 655-669 , v
    CrossrefPubMedGoogle Scholar
  • 31 Gerend MA, Pai M. Social determinants of Black-White disparities in breast cancer mortality: a review. Cancer Epidemiol Biomarkers Prev 2008; 17 (11) 2913-2924
    CrossrefPubMedGoogle Scholar
  • 32 McClelland S, Deville C, Thomas CJr, Jaboin JJ. An overview of disparities research in access to radiation oncology care. J Radiat Oncol 2016; 5 (04) 437-444
    CrossrefPubMedGoogle Scholar
  • 33 Rieken S, Habermehl D, Welzel T. et al. Long term toxicity and prognostic factors of radiation therapy for secreting and non-secreting pituitary adenomas. Radiat Oncol 2013; 8 (01) 18
    CrossrefPubMedGoogle Scholar
  • 34 Solda F, Fersht T. Radiotherapy for pituitary tumours. In: De Groot LJ, Chrousos G, Dungan K. et al. Endotext [Internet]. South Dartmouth, MA: 2000
    Google Scholar